Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted PET imaging agent in prostate cancer. The agent has now been added ...
MONROE TOWNSHIP, NJ, & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, ...
− Based on data from prospective Phase 3 LIGHTHOUSE and SPOTLIGHT studies in newly diagnosed and recurrent prostate cancer – MONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)--Blue Earth ...
This approval allows Zydus Lifesciences to enter the promising US market, where Leuprolide Acetate injection generates $69 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback